Orexo: Zubsolv Rx Data week 6, 2017

According to latest Symphony Health Solutions Rx data, Zubsolv tablets showed a market share of 5.57% (5.61%), 4-week rolling average. The total number of Zubsolv tablets sold week 6 (5) reaching 325,107 (321,704). Zubsolv prescriptions (TRx) recorded a market share of 5.59% (5.59%), 4-week rolling average. Total number of prescriptions reaching 11,659 (11,777) during the week.

The overall market (buprenorphine/naloxone) showed a y/y growth rate of 8.9% (8.9%) (4-week rolling average unit sales). TRx showed a y/y growth rate by 10.7% (10.4%) (4-week rolling average).

Författaren ägde vid analystillfället aktier i bolaget.

Fler bolagsanalyser

Här listas fler bolagsanalyser ifrån Redeyes analysavdelning.

Publicerad Rubrik Analystyp
2017-03-22 Analys
2017-03-21 Update
2017-03-21 Update
2017-03-17 Update
2017-03-16 Update
2017-03-14 Update
2017-03-14 Update
2017-03-10 Update
2017-03-10 Update
2017-03-07 Update
2017-03-07 Update
2017-03-07 Update
2017-03-07 Update
2017-03-06 Update
2017-03-06 Update
2017-03-03 Update
2017-03-03 Update
2017-03-03 Update
2017-03-03 Update
2017-03-01 Update
2017-02-28 Update
2017-02-27 Update
2017-02-27 Update
2017-02-27 Update
2017-02-27 Update